Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
Clinical trial NCT05033756 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05033756
- Sponsor
- Institut fuer Frauengesundheit
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-30
- Primary completion
- 2025-01-01
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.